Avastin authorized for UK advanced cervical cancer patients
Swiss drug major Roche’s (ROG: SIX) Avastin (bevacizumab) has been authroized in the UK in combination with standard chemotherapy for the treatment of women with advanced cervical cancer. This is the first new treatment authorized in a decade for advanced cervical cancer patients in the UK, said Roche.
Avastin, which has been aprroved for this indication by the European Commission, has been available ahead of licence to eligible patients in England via individual requests to the Cancer Drugs Fund (CDF) since March 2014. The decision by NHS England to add Avastin to the CDF list made England the first country in the world to offer Avastin to patients with advanced cervical cancer. Since being listed by the CDF, at least 149 individual applications have been made to access the treatment for use in advanced cervical cancer. Avastin is also indicated for the treatment of several other types of cancer, including bowel, ovarian and breast cancers.
Study details
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze